Drug intelligence / Profile preview

TNV108

Development stage: Preclinical
Lead developer: Tenvie Therapeutics
Modality: Small Molecules

Overview

TNV108 is a **small molecule** SARM1 inhibitor being developed by **Tenvie Therapeutics** for **peripheral neuropathies**. It is described as a **peripherally restricted allosteric inhibitor** of Sterile Alpha and TIR Motif Containing 1, a design intended to limit central nervous system penetration while modulating SARM1-driven axonal degeneration biology in the peripheral nervous system. Based on the provided context, TNV108 is in **preclinical development**.

Targets

SARM1

Beyond the preview

Go deeper on TNV108.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TNV108.

Explore the full profile